Welcome To
Acadia Broadcasting NewsThe Latest and Greatest ContentYour Trusted Local Source


Pfizer’s Covid Pill Has Little Benefit for Younger Population: A Study

By Katie Nicholls Aug 25, 2022 | 10:56 AM

danilo.alvesd / Unsplash

Pfizer’s COVID-19 pill (Paxlovid) isn’t that effective in the younger population, according to a new study.

A recent study was published, showing the effectiveness of the pill after results from 109,000 patients were reviewed. The study, out of Israel, showed that those between 40 and 65 had little to no measurable benefit from taking Paxlovid.

However, it did reduce hospitalizations of people who were 65+ when they took the antibiotic shortly after becoming infected by COVID.

The style of the study is rare since it comes from patients who knew what they were taking the pill, versus a randomized study within a control group, which is more broadly accepted.

The results show a shift in the pandemic in that many have built immunity from having been previously infected and or a combination with a vaccine.

The CDC in the US estimates that 95 per cent of Americans over the age of 16 have some sort of immunity from the virus.


Leave a Reply